中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 10
Oct.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(10): 2474-2477

Risk factors for polycystic ovary syndrome with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.10.046
  • 1a.

    Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110004, China

  • 1b.

    Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang 110004, China

  • 2.

    Department of Endocrinology, The Third People's Hospital of Dalian, Dalian, Liaoning 116033, China

Research funding:

National Natural Science Foundation of China (81570765)

  • Received Date: 2021-02-04
  • Accepted Date: 2021-02-20
  • Published Date: 2021-10-20
    Abstract
  • Polycystic ovary syndrome (PCOS) manifests as a series of disorders in reproductive system, endocrine, and metabolism, and there is a significant increase in the prevalence rate of nonalcoholic fatty liver disease (NAFLD) in the population with PCOS. At present, the risk factors for PCOS with NAFLD have not been fully clarified. This article introduces the research advances in PCOS with NAFLD from the aspects of hyperandrogenism, insulin resistance, obesity, dyslipidemia, chronic low-grade inflammation, and intestinal flora imbalance, so as to provide ideas and methods for improving the awareness and management of PCOS with NAFLD.

     

    • FullText(HTML)
  • loading
    • References(42)
  • [1]
    ROCHA AL, OLIVEIRA FR, AZEVEDO RC, et al. Recent advances in the understanding and management of polycystic ovary syndrome[J]. F1000Res, 2019, 8: F1000 Faculty Rev-565. DOI: 10.12688/f1000research.15318.1.
    [2]
    CONWAY G, DEWAILLY D, DIAMANTI-KANDARAKIS E, et al. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology[J]. Eur J Endocrinol, 2014, 171(4): p1-p29. DOI: 10.1530/EJE-14-0253.
    [3]
    WANG J, WU D, GUO H, et al. Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome[J]. Life Sci, 2019, 236: 116940. DOI: 10.1016/j.lfs.2019.116940.
    [4]
    ZENG X, XIE YJ, LIU YT, et al. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity[J]. Clin Chim Acta, 2020, 502: 214-221. DOI: 10.1016/j.cca.2019.11.003.
    [5]
    IGNATOV A, ORTMANN O. Endocrine risk factors of endometrial cancer: Polycystic ovary syndrome, oral contraceptives, infertility, tamoxifen[J]. Cancers (Basel), 2020, 12(7): 1766. DOI: 10.3390/cancers12071766.
    [6]
    SUNAMI Y. NASH, Fibrosis and hepatocellular carcinoma: Lipid synthesis and glutamine/acetate signaling[J]. Int J Mol Sci, 2020, 21(18): 6799. DOI: 10.3390/ijms21186799.
    [7]
    PAFILI K, RODEN M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans[J]. Mol Metab, 2021, 50: 101122. DOI: 10.1016/j.molmet.2020.101122.
    [8]
    SALVA-PASTOR N, LÓPEZ-SÁNCHEZ GN, CHÁVEZ-TAPIA NC, et al. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population[J]. Ann Hepatol, 2020, 19(3): 251-257. DOI: 10.1016/j.aohep.2020.01.004.
    [9]
    ZHANG J, HU J, ZHANG C, et al. Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease[J]. Exp Ther Med, 2018, 15(5): 4259-4264. DOI: 10.3892/etm.2018.5932.
    [10]
    SARKAR M, TERRAULT N, CHAN W, et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis[J]. Liver Int, 2020, 40(2): 355-359. DOI: 10.1111/liv.14279.
    [11]
    QIAN ZW, YAO Q, ZHOU G, et al. Advances in neuroendocrine mechanism of polycystic ovary syndrome[J]. J Int Reprod Health/Fam Plan, 2021, 40(1): 79-83. DOI: 10.12280/gjszjk.20200249.

    钱紫薇, 姚琦, 周阁, 等. 多囊卵巢综合征神经内分泌病因机制的研究进展[J]. 国际生殖健康/计划生育杂志, 2021, 40(1): 79-83. DOI: 10.12280/gjszjk.20200249
    [12]
    WU J, YAO XY, SHI RX, et al. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: An update meta-analysis[J]. Reprod Health, 2018, 15(1): 77. DOI: 10.1186/s12978-018-0519-2.
    [13]
    BARANOVA A, TRAN TP, AFENDY A, et al. Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS)[J]. J Transl Med, 2013, 11: 133. DOI: 10.1186/1479-5876-11-133.
    [14]
    SAEZ-LOPEZ C, BARBOSA-DESONGLES A, HERNANDEZ C, et al. Sex hormone-binding globulin reduction in metabolic disorders may play a role in NAFLD development[J]. Endocrinology, 2017, 158(3): 545-559. DOI: 10.1210/en.2016-1668.
    [15]
    ZHANG Y, MENG F, SUN X, et al. Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver[J]. Oncotarget, 2018, 9(26): 18180-18197. DOI: 10.18632/oncotarget.24477.
    [16]
    CONDORELLI RA, CALOGERO AE, DI MAURO M, et al. Androgen excess and metabolic disorders in women with PCOS: Beyond the body mass index[J]. J Endocrinol Invest, 2018, 41(4): 383-388. DOI: 10.1007/s40618-017-0762-3.
    [17]
    WELT CK, DURAN JM. Genetics of polycystic ovary syndrome[J]. Semin Reprod Med, 2014, 32(3): 177-182. DOI: 10.1055/s-0034-1371089.
    [18]
    LU CY, QIAN Y. Mechanisms and drug therapy of insulin resistance in polycystic ovary syndrome[J]. Medical Recapitulate, 2020, 26(22): 4504-4509, 4514. DOI: 10.3969/j.issn.1006-2084.2020.22.026.

    陆超亦, 钱云. 多囊卵巢综合征胰岛素抵抗机制与药物治疗[J]. 医学综述, 2020, 26(22): 4504-4509, 4514. DOI: 10.3969/j.issn.1006-2084.2020.22.026.
    [19]
    HARSHA VARMA S, TIRUPATI S, PRADEEP T, et al. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome[J]. Diabetes Metab Syndr, 2019, 13(2): 1065-1069. DOI: 10.1016/j.dsx.2018.12.020.
    [20]
    BUZZETTI E, PINZANI M, TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048. DOI: 10.1016/j.metabol.2015.12.012.
    [21]
    HIGUCHI N, KATO M, TANAKA M, et al. Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease[J]. Exp Ther Med, 2011, 2(6): 1077-1081. DOI: 10.3892/etm.2011.328.
    [22]
    CHATTERJEE A, BASU A, DAS K, et al. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis[J]. Ann Hepatol, 2020, 19(5): 472-481. DOI: 10.1016/j.aohep.2020.06.009.
    [23]
    FURUHASHI M, SAITOH S, SHIMAMOTO K, et al. Fatty acid-binding protein 4 (FABP4): Pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases[J]. Clin Med Insights Cardiol, 2014, 8(Suppl 3): 23-33. DOI: 10.4137/CMC.S17067.
    [24]
    MOYLAN CA, PANG H, DELLINGER A, et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease[J]. Hepatology, 2014, 59(2): 471-482. DOI: 10.1002/hep.26661.
    [25]
    XIE LD, ZHANG YN, GONG LF, et al. Pathogenesis of polycystic ovary syndrome with insulin resistance[J]. Matern Child Health Care China, 2019, 34(8): 1926-1929. DOI: 10.7620/zgfybj.j.issn.1001-4411.2019.08.75.

    谢来娣, 张伊娜, 龚丽芬, 等. 多囊卵巢综合征伴胰岛素抵抗相关发病机制研究[J]. 中国妇幼保健, 2019, 34(8): 1926-1929. DOI: 10.7620/zgfybj.j.issn.1001-4411.2019.08.75.
    [26]
    SHENGIR M, KRISHNAMURTHY S, GHALI P, et al. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome[J]. World J Gastroenterol, 2020, 26(44): 7046-7060. DOI: 10.3748/wjg.v26.i44.7046.
    [27]
    O'REILLY MW, HOUSE PJ, TOMLINSON JW. Understanding androgen action in adipose tissue[J]. J Steroid Biochem Mol Biol, 2014, 143: 277-284. DOI: 10.1016/j.jsbmb.2014.04.008.
    [28]
    BARBER TM, HANSON P, WEICKERT MO, et al. Obesity and polycystic ovary syndrome: Implications for pathogenesis and novel management strategies[J]. Clin Med Insights Reprod Health, 2019, 13: 1179558119874042. DOI: 10.1177/1179558119874042.
    [29]
    HU W, LI L, YANG M, et al. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans[J]. J Clin Endocrinol Metab, 2013, 98(1): 290-298. DOI: 10.1210/jc.2012-2466.
    [30]
    WANG GX, ZHAO XY, MENG ZX, et al. The brown fat-enriched secreted factor Nrg4 preserves metabolic homeostasis through attenuation of hepatic lipogenesis[J]. Nat Med, 2014, 20(12): 1436-1443. DOI: 10.1038/nm.3713.
    [31]
    CHANG ML, YANG Z, YANG SS. Roles of adipokines in digestive diseases: Markers of inflammation, metabolic alteration and disease progression[J]. Int J Mol Sci, 2020, 21(21). DOI: 10.3390/ijms21218308.
    [32]
    MAFFAZIOLI G, LOPES CP, HEINRICH-OLIVEIRA V, et al. Prevalence of metabolic disturbances among women with polycystic ovary syndrome in different regions of Brazil[J]. Int J Gynaecol Obstet, 2020, 151(3): 383-391. DOI: 10.1002/ijgo.13374.
    [33]
    TARANTO D, GUIMARÃES T, COUTO CA, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: Associated factors and noninvasive fibrosis staging in a single Brazilian center[J]. Arch Endocrinol Metab, 2020, 64(3): 235-242. DOI: 10.20945/2359-3997000000242.
    [34]
    MARÍ M, CABALLERO F, COLELL A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis[J]. Cell Metab, 2006, 4(3): 185-198. DOI: 10.1016/j.cmet.2006.07.006.
    [35]
    IOANNOU GN, SUBRAMANIAN S, CHAIT A, et al. Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH[J]. J Lipid Res, 2017, 58(6): 1067-1079. DOI: 10.1194/jlr.M072454.
    [36]
    TOMITA K, TERATANI T, SUZUKI T, et al. Acyl-CoA: Cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells[J]. J Hepatol, 2014, 61(1): 98-106. DOI: 10.1016/j.jhep.2014.03.018.
    [37]
    RUDNICKA E, KUNICKI M, SUCHTA K, et al. Inflammatory markers in women with polycystic ovary syndrome[J]. Biomed Res Int, 2020, 2020: 4092470. DOI: 10.1155/2020/4092470.
    [38]
    SPRITZER PM, LECKE SB, SATLER F, et al. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome[J]. Reproduction, 2015, 149(5): r219-r227. DOI: 10.1530/REP-14-0435.
    [39]
    KRISHNAN A, MUTHUSAMI S, PERIYASAMY L, et al. Effect of DHT-induced hyperandrogenism on the pro-inflammatory cytokines in a rat model of polycystic ovary morphology[J]. Medicina (Kaunas), 2020, 56(3): 100. DOI: 10.3390/medicina56030100.
    [40]
    GARCIA-BELTRAN C, MALPIQUE R, CARBONETTO B, et al. Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments[J]. Pediatr Obes, 2021, 16(4): e12734. DOI: 10.1111/ijpo.12734.
    [41]
    CHU W, HAN Q, XU J, et al. Metagenomic analysis identified microbiome alterations and pathological association between intestinal microbiota and polycystic ovary syndrome[J]. Fertil Steril, 2020, 113(6): 1286-1298. e4. DOI: 10.1016/j.fertnstert.2020.01.027.
    [42]
    ZHOU L, NI Z, YU J, et al. Correlation between fecal metabolomics and gut microbiota in obesity and polycystic ovary syndrome[J]. Front Endocrinol (Lausanne), 2020, 11: 628. DOI: 10.3389/fendo.2020.00628.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (529) PDF downloads(41) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return